Aptus Pharma Ltd.
BBSE:APPL501.50
INR
+9.80
(+1.99%)
ISIN
INE15XJ01010
Return %
Stock
S&P 500
1Y
907.35
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Ghanshyam Vinubhai Pansuriya
- Full Time Employees
- 91
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Rajkot India
- IPO Date
- Sep 30, 2025
- Website
- aptus-pharma.com
- Similar Companies
- Business
- Aptus Pharma Ltd. is an India-based pharmaceutical company primarily engaged in the marketing, commercialization, and distribution of finished pharmaceutical formulations and healthcare products across domestic and international markets. Founded in 2010 and headquartered in Ahmedabad, Gujarat, with its corporate office located in Rajkot, Gujarat, the company operates through an asset-light business model, partnering with certified third-party contract manufacturing facilities for formulation production while directing proprietary brand management, sales operations, and regulatory oversight. The company offers a diversified therapeutic portfolio comprising approximately 200 formulations organized across four specialized business divisions: Aptus Pharma (Pioneer Division), which focuses on acute care pharmaceuticals; Aptus CD Care, which concentrates on chronic disease therapies; Aptus Wellcare, which markets nutraceuticals and wellness items; and Aptus Global, which oversees international trade. Systematic product categories and dosage forms include oral solid dosages, such as immediate-release tablets, sustained-release tablets, and hard and soft gelatin capsules; oral liquid preparations, including therapeutic syrups, paediatric suspensions, oral solutions, and drops; sterile injectables and parenteral formulations, consisting of intravenous infusions, ampoules, and vials; topical treatments and dermatologicals, including antiseptic creams, analgesic ointments, lotions, and transdermal gels; and dietary supplements, encompassing multivitamin formulations, mineral complexes, nutritional sachets, and medicated powders. Commercial brands marketed by the company include Aptifresh, Aptiglim, Aptichym, Aptida, Aptidol, Aptidox, Apbile, Apora, Chilkul, Koltus, Telbira, and Aptirub, targeting healthcare professionals, retail pharmacies, and institutional buyers. In recent corporate developments, the enterprise executed a major structural reorganization, converting from a private company into a public entity and officially changing its corporate name from Aptus Pharma Private Limited to Aptus Pharma Limited in December 2024. In September 2025, Aptus Pharma completed an Initial Public Offering (IPO) on the BSE SME platform (BSE: APPL), raising approximately INR 13.02 crore through a fresh issue of equity shares to fund working capital requirements and support operational expansion. Over the past two years, the company has broadened its therapeutic scope by scaling its cardiovascular and antidiabetic product lines under the Aptus CD Care division, expanding domestic distribution networks across semi-urban and rural healthcare channels, and accelerating international registration efforts under the Aptus Global division to establish strategic market presence in emerging and semi-regulated overseas regions.